Literature DB >> 17267894

Management of undifferentiated embryonal sarcoma of the liver in pregnancy.

Fergus P McCarthy1, Marion Harris, Louise Kornman.   

Abstract

BACKGROUND: Undifferentiated embryonal sarcoma of the liver is a rare mesenchymal neoplasm with a poor prognosis. Most cases occur in children, with few cases reported in adults. Our patient was a woman whose pregnancy was complicated by the recurrence of metastatic undifferentiated embryonal sarcoma of the liver. CASE: In the medical literature only two other women have been described with metastatic undifferentiated embryonal sarcoma of the liver in pregnancy. This is the first reported case of undifferentiated embryonal sarcoma of the liver recurring in and requiring treatment during pregnancy. Radio frequency ablation was used to try to control sites of hepatic disease recurrence during the pregnancy. The patient gave birth to a healthy son before requiring further palliative chemotherapy.
CONCLUSION: This case highlights the fact that cancer not infrequently complicates pregnancy and can require treatment, in this case with radio frequency ablation. The case also illustrates a range of complex issues that arise when a patient with cancer has a pregnancy: the doctor's recommendations, the patient's right to choose, the well-being of the infant, and the unpredictable behavior of cancer.

Entities:  

Mesh:

Year:  2007        PMID: 17267894     DOI: 10.1097/01.AOG.0000252833.73033.44

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  2 in total

1.  Diagnosis and Treatment of an Undifferentiated Embryonal Sarcoma of the Liver in a 37-Week Pregnant Woman: A Case Report.

Authors:  Tran Manh Hung; Tran Que Son; Tran Thi Phuong; Hoang Van Minh
Journal:  Int J Womens Health       Date:  2021-11-16

2.  Undifferentiated embryonal sarcoma of the liver in a child: A case report and review of the literature.

Authors:  Jie Gao; Liming Fei; Sheng Li; Kai Cui; Jianbo Zhang; Fachang Yu; Bo Zhang
Journal:  Oncol Lett       Date:  2012-12-19       Impact factor: 2.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.